Quantification of MMP-2 and TIMP-1 expressions in breast cancer

Abstract

Background and Aims: MMP-2 and TIMP-1 are vital molecules in the remodeling of the extracellular matrix, and they have a critical role in the metastatic process of breast cancer. This study aimed to detect expression levels of MMP-2 and TIMP-1 genes by Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and identify their potential roles in breast cancer prognosis. Methods: MMP-2 and TIMP-1 gene expression levels in 17 breast cancer tumor tissues and normal breast tissue were examined. The expression levels of MMP-2 and TIMP-1 were analyzed by qRT-PCR. The association between the expression levels of MMP-2 and TIMP-1 and clinicopathological manifestations of breast cancer was examined. Results: Lower gene expression levels of MMP-2 and TIMP-1 were detected in tumors compared to the controls. A statistical correlation was not observed between the expression level of MMP-2, TIMP-1, and clinicopathological parameters (tumor grade, lymph node involvement, hormone receptor status). Conclusion: Our findings have been suggesting that expression profiles of MMP-2 and TIMP-1 might be independent prognostic and predictive biomarkers for breast cancer. These biomarkers are candidate molecules for personalized therapy. MMP-2 and TIMP-1 expression patterns will also aid in the identification of more precise and targeted subgroups of breast cancer.

Keywords

• Breast cancer
• MMP2 metalloproteinase
• TIMP-1

References

1. Abdollahi, A., Nozarian, Z., & Nazar, E. (2019). Association Between Expression of Tissue Inhibitors of Metalloproteinase-1, Matrix Me-talloproteinase-2, and Matrix Metalloproteinase-9 and Axillary Lymph Nodes Metastasis in Patients with Breast Cancer. Interna-tional Journal of Preventive Medicine, 10, 127. https://doi:10.4103/ ijpvm.IJPVM_355_16 google scholar
2. Arpino, V., Brock, M., & Gill, S. E. (2015). The role of TIMPs in regula-tion of extracellular matrix proteolysis. Matrix Biology: Journal of the International Society for Matrix Biology, 44-46, 247-254. https:// doi.org/10.1016/j.matbio.2015.03.005 google scholar
3. Chen, Y., Wang, X., Chen, G., Dong, C., & Zhang, D. (2015). The Im-pact of Matrix Metalloproteinase 2 on Prognosis and Clinicopath-ology of Breast Cancer Patients : A Systematic Meta-Analysis. Plos One, 10, 1-16. https://doi.org/10.1371/journal.pone.0121404 google scholar
4. Cine, N., Baykal, A.T., Sunnetci, D., Canturk, Z., Serhatli, M., & Savli, H. (2014). Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer. Oncology Reports, 32, 1078-1086. https:// doi.org/10.3892/or.2014.3277 google scholar
5. Daniele, A., Abbate, I., Oakley, C., Casamassima, P., Savino, E., Casa-massima, A ... Divella, R. (2016). Clinical and prognostic role of ma-trix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review. International Journal of Biochemistry, 77, 91-101. https://doi: 10.1016/j.biocel.2016.06.002 google scholar
6. Dechaphunkul, A., Phukaoloun, M., Kanjanapradit, K., Graham, K., Ghosh, S., Santos, C., & Mackey, J. R. (2012). Prognostic signifi-cance of tissue inhibitor of metalloproteinase-1 in breast cancer. International Journal of Breast Cancer, 2012, 290854. https://doi. org/10.1155/2012/290854 google scholar
7. Decock, J., Hendrickx, W., Wildiers, H., Christiaens MR, Neven P, Dri-jkoningen M, & Paridaens, R. (2005). Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clinical & Experimental Metastasis, 22, 495-502. https:// doi.org/10.1007/s10585-005-3992-2 google scholar
8. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Pineros, M., Znaor, A., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer, 144, 1941-1953. https:// doi.org/10.1002/ijc.31937 google scholar

9. Figueira, R. C. S., Gomes, L. R., Neto, J. S., Silva, F.C., Silva, I. D. C. G., &Sogayar M. C. (2009). Correlation between MMPs and their in-hibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer, 11, 1-11. https:// doi:10.1186/1471-2407-9-20. google scholar
10. Guo, X., Wu, Y., Hathaway, H. J., & Hartley, R. S. (2012). Microenvi-romental control of the breast cancer cell cycle. The Anatomical Record, 295, 553-562. https://doi:10.1002/ar.22417 google scholar
11. Hadler-Olsen, E., Winberg, J. O., & Uhlin-Hansen, L. (2013). Matrix metalloproteinases in cancer: Their value as diagnostic and prog-nostic markers and therapeutic targets. Tumor Biology, 34, 20412051. https://doi:10.1007/s13277-013-0842-8 google scholar
12. Hirvonen, R., Talvensaari-Mattila, A., Paakkö, P., & Turpeenniemi-Hujanen, T. (2003). Matrix metalloproteinase-2 (MMP-2) in T(1-2) N0 breast carcinoma. Breast Cancer Research and Treatment, 77, 85-91. https://doi.org/10.1023/a:1021152910976 google scholar
13. Huang, J., Ang, L., Liu, M. Q., Hu, H. G., Wang, J., & Zou, Q. (2014).Serum and tissue expression of gelatinase and Twist in breast cancer. European Review for Medical and Pharmacological Sciences, 18, 2662-2669. google scholar
14. Jezierska, A., & Motyl, T. (2009). Matrix metalloproteinase-2 in-volvement in breast cancer progression: a mini-review. Medical Science Monitor, 15, RA32-RA40. https://pubmed.ncbi.nlm.nih. gov/19182722/ google scholar
15. Kousidou, O, C., Roussidis, A. E., Theocharis, A. D., & Karamanos, N. K. (2004). Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is _______________________________ 217associated with their invasive potential. Anticancer Research, 24, 4025-4030. google scholar
16. Kuvaja, P,, Talvensaari-Mattila, A., Paakkö, P,, & Turpeenniemi-Hu-janen, T. (2005). The absence of immunoreactivity for tissue inhib-itor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carci-noma. Oncology, 68, 196-203. https://doi.org/10.1159/000086774 google scholar
17. Leppa, S,, Saarto, T,, Vehmanen, L,, Blomqvist, C,, & Elomaa, I, A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. (2004). Clinical Cancer Research, 10, 1057-1063. https://doi:10.1158/1078-0432.ccr-03-0047. google scholar
18. Lipton, A., Leitzel, K., Chaudri-Ross, H. A., Evans, D. B., Ali, S. M., Demers L, ...Carney, W. (2008). Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. Journal of Clinical Oncology, 26, 2653-2658. https:// doi:10.1200/JCO.2007.15.4336 google scholar
19. Lu, L.S., Chen, L., Ding, W. X., Li, K., &Wu, J. J. (2012). Elevated ex-pression of both MDR1 and MMP-2 genes in metastasized lymph node of invasive ductal breast cancer. European Review for Medi-cal and Pharmacological Sciences, 16, 2037-2043. google scholar
20. Mahmood, N. A., Fakhoury, R. M., Yaseen, N. Y., & Moustafa, M. E. ( 2015). Matrix Metalloproteinases MMP2 and MMP9 Expression in Stages II-III Breast Cancer in Iraqi Women. Journal of Biomedical Science, 1, 30-37. google scholar
21. Nakopoulou, L., Giannopoulou, I., Stefanaki, K., Panayotopoulou, E., Tsirma, I., Alexandrou, P.,.. Davaris, P. (2002). Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 ( TIMP-1 ) in breast carcinomas is correlated with adverse prognosis. The Journal of Pathology, 197, 307-313. https://doi:10.1002/path.1129">https://doi:10.1002/path.1129. Nakopoulou, L., Giannopoulou, I., Lazaris, A., Alexandrou, P., Tsirm-pa, I., Markaki, S., Panayotopoulou, E., & Keramopoulos, A. (2003). The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003, 111, 1027-1036. https://doi: 10.1111/j.1600-0463.2003.apm1111105.x. google scholar
22. Öncel, M. (2012). Matriks Metalloproteinazlar ve Kanser. Euro-pean Journal of Basic Medical Sciences, 2, 91-100. https://doi. org/10.21601/ejbms/9185 google scholar
23. Savlı, H., Aalto, Y., Nagy, B., Knuutila, S.,& Pakkala, S. (2002). Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: A cDNA array study. British Journal of Haematology, 118, 1065-1070. https://doi:10.1046/j.1365-2141.2002.03734.x google scholar
24. Savlı, H., Karadenizli, A,, Kolaylı, F., Gündeş, S., Özbek, U., & Vahaboğlu, H. (2003). Expression stability of six housekeeping genes: A proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. Journal of Medical Microbiology, 52, 403-408. https://doi:10.1099/ jmm.0.05132-0 google scholar
25. Sieuwerts, A. M., Usher, P.A., Meijer-van Gelder, M. E., Timmer-mans, M., Martens, J.W., Brünner, N., ...Foakens, J. A. (2007). Con-centrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clinical Chemistry, 53, 1280-1288. https://doi:10.1373/ clinchem.2006.082800. google scholar
26. Talvensaari-Mattila, A., & Paakkö, P., Turpeenniemi-Hujanen, T. (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. British Journal of Cancer, 89, 12701275. https://doi:10.1038/sj.bjc.6601238 google scholar
27. Talvensaari-Mattila, A., & Turpeenniemi-Hujanen, T. (2005). High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Research and Treatment, 89, 29-34. https://doi.org/10.1007/s10549-004-1006-8 google scholar
28. Ünçel., M, Aköz., G, Yıldırım., Z, Pişkin., G, Değirmenci M, Kahraman DS, . Diniz., G. (2015). Evaluation of clinicopathological features of breast cancer according to the molecular subtypes. Journal of Tepecik Education and Research Hospital, 25, 151-156. https:// doi:10.5222/terh.2015.151 google scholar
29. Wu, Z. S., Wu, Q., Yang, J. H., Wang, H. Q., Ding, X. D., Yang, F., & Xu, X. C. (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. International Journal of Cancer, 122, 2050-2056. https://doi.org/10.1002/ijc.23337 google scholar
30. Würtz, S. 0., Schrohl, A. S., Mouridsen, H., & Brünner, N. (2008). TIMP-1 as a tumor marker in breast cancer - An update. Acta Oncolog-ica (Madr), 47, 580-590. https://doi:10.1080/02841860802022976. Würtz S. 0., Moller, S., Mouridsen, H., Hertel, P B., Friis, E., & Brünner N. (2008). Plasma and serum levels of tissue inhibitor of metal-loproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Molecular & Cellular Proteomics, 7, 424-430. https://doi:10.1074/mcp.M700305-MCP200. google scholar
31. Yadav, L., Puri, N., Rastogi. V., Satpute, P., Ahmad, R., & Kaur, G. (2014). Matrix metalloproteinases and cancer - Roles in threat and therapy. The Asian Pacific Journal of Cancer Prevention, 15, 10851091. http://dx.doi.org/10.7314/APJCP.2014.15.3.1085 google scholar
32. Zhang, M., Teng, X., Guo, X., Li, Z., Han, J., & Yao, L. (2013). Expres-sion of tissue levels of matrix metalloproteinases and their inhibi-tors in breast cancer. The Breast, 22, 330-334. https://doi:10.1016/j. breast.2012.08.002. google scholar